Thermo Fisher Scientific showcases end-to-end diagnostic and laboratory solutions targeting unmet clinical needs at ADLM 2026

Thermo Fisher Scientific will bring its latest diagnostic innovations, recent regulatory achievements, and expanded capabilities to the Association for Diagnostics and Laboratory Medicine Conference in Anaheim, California, running from 26 to 30 July 2026. Covering specialty diagnostics, quality management, and the full diagnostic continuum, the company’s participation reflects a sustained commitment to addressing unmet clinical needs through reliable, purpose-built diagnostic and workflow solutions.

“Laboratories today face growing pressure to deliver faster, more accurate results while managing operational complexity,” said Puneet Sarin, Senior Vice President and President, Specialty Diagnostics, Thermo Fisher. “At the same time, the traditional boundaries between research, translational medicine and diagnostics continue to blur as science advances and healthcare evolves. With the breadth of our diagnostics portfolio, including instruments, assays and digital solutions, Thermo Fisher is uniquely positioned to help laboratories accelerate innovation, enable precision medicine and deliver the reliable insights clinicians need to improve patient care.”

The EXENT Solution, Thermo Fisher’s fully integrated and automated mass spectrometry platform developed to support the diagnosis of multiple myeloma and related disorders, recently received 510(k) clearance from the US Food and Drug Administration. More than 176,000 people globally receive a multiple myeloma diagnosis each year according to the International Myeloma Foundation, yet the existing diagnostic pathway can be slow and uncertain, frequently relying on subjective interpretation of results. By pairing heightened sensitivity with automated workflows, the EXENT System helps clinical laboratories produce accurate results that support swift, confident diagnoses and better-informed clinical decisions. The system is now available for clinical use across Australia, Belgium, Brazil, Canada, France, Germany, Italy, the Netherlands, New Zealand, Spain, Switzerland, the United Kingdom, and the United States.

Within oncology, the Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer received FDA approval in 2025 as a companion diagnostic for sunvozertinib in non-small cell lung cancer and for tumour profiling in formalin-fixed paraffin-embedded samples. The system enables next-generation sequencing results in as little as 24 hours, allowing care teams to act on genomic information without prolonging an already difficult waiting period.

In autoimmune disease diagnostics, the EliA CTD 13 Screen received FDA 510(k) clearance in June 2026, giving clinical laboratories a new tool for systemic connective tissue disease testing. Designed to support clinicians and laboratories managing patients with complex autoimmune conditions, the assay streamlines testing workflows and delivers results that guide targeted follow-up and more informed clinical decisions. Available on the Phadia 250 instrument, it is intended to aid in diagnosing systemic autoimmune connective tissue diseases including systemic lupus erythematosus, Sjögren’s syndrome, systemic sclerosis, polymyositis, dermatomyositis, and mixed connective tissue disease, when used alongside other laboratory and clinical findings.

Thermo Fisher will also highlight its B·R·A·H·M·S biomarker testing portfolio, which supports earlier diagnosis and guides treatment planning in life-threatening conditions such as sepsis and preeclampsia. Built around the Thermo Scientific B·R·A·H·M·S KRYPTOR Analyzers, the portfolio encompasses procalcitonin testing for antibiotic stewardship in sepsis management and the PreClara Ratio, the first FDA-cleared biomarker test for preeclampsia risk assessment, addressing a condition that remains a leading contributor to maternal and neonatal illness and death worldwide.

---

---

Related Topics and Keywords

ADLM 2026, Thermo Fisher Scientific